logo Ibionextlogo Ibionext
  • HOME
  • ABOUT US
  • STRATEGY
  • TEAM
  • OUR COMPANIES
  • NEWS & MEDIA
  • CONTACT
  • Français
Twitter
LinkedIn

T-Heart appoints Sarah Sorrel as independent board member

November 29, 2022Press releasesIbionext

Paris, France, November 29th 2022 – T-Heart, a MedTech company developing a truly novel and differentiated transcatheter tricuspid prosthetic heart valve specifically designed for tricuspid regurgitation, today announced it has appointed Sarah Sorrel as its first independent member of the Board of Directors.

Sarah Sorrel has more than 30 years of experience in medical device regulation and clinical trials with an emphasis on emerging technologies. She founded and successfully managed MedPass International, a leading European CRO, regulatory and reimbursement consultancy, that specializes in medical device development and market access, before its acquisition by ICON plc in 2020. Sarah is American and holds a degree in Engineering and Applied Science from Yale University.

 

Sarah Sorrel joins the T-Heart Board of Directors when the company is preparing its First in Human / Early Feasibility Study, bringing a valuable experience and expertise to its execution. Soad El Ghazouani, CEO of T-Heart said: “We are excited to have an independent board member with such considerable experience in MedTech, and more specifically in the transcatheter heart valve field, joining the board at T-Heart at a key moment for the company. Sarah’s experience and extensive knowledge of healthcare regulations will be an invaluable asset as we advance towards the clinic.”

Ms. Sorrel added: “I am honored to join the T-Heart Board of Directors and convinced that tricuspid is the next key step in the transcatheter heart valve field.  I look forward to contributing to T-Heart’s important objective to bring a perfectly adapted and differentiated solution to patients suffering from severe tricuspid regurgitation and hopefully significantly improve their quality of life. “

Ms. Sorrel is the third female out of five representatives to join the board of T-Heart.

 

CONTACTS

 

T-HEART
Soad El-Ghazouani

+33 (0)1 85 73 27 05

selghazouani@theartvalve.com

 

ABOUT T-HEART

 

T-Heart is a French MedTech company focused on the treatment of Tricuspid Regurgitation, a true medical unmet need. Tricuspid regurgitation is a progressive condition in which blood leaks backward through the tricuspid valve, potentially leading to heart failure and death.  The transcatheter tricuspid market represents a $3.0+ billion potential opportunity, although currently, limited treatment options exist to address this market.

T-Heart has developed a truly novel and differentiated transcatheter tricuspid prosthetic heart valve specifically designed for tricuspid heart valve regurgitation, thereby addressing the specific anatomical challenges.  Moreover, T-Heart’s unique design enables the interventional cardiologist to replace the diseased tricuspid valve with a simple one-step technique and allows for broad applicability to a larger patient population with minimal device sizes.

For more information: www.theartvalve.com

 

T-Heart was co-founded in late 2018 with iBionext, a company builder and investor that supports and finances the development of companies with a strong technological breakthrough in HealthTech in Paris, France.

Since its inception, T-Heart has assembled an impressive team, comprised of management and external experts, has successfully proved the concept through pre-clinical testing and initiated its Q-Sub for EFS with the FDA.

For more information: www.ibionext.com

Previous post BrainEver and 3P Biopharmaceuticals collaborate on development of recombinant human homeoprotein Engrailed-1 Next post A comprehensive look at everything that happened in Prohesee in 2022

SEARCH

ARCHIVES

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

CATEGORIES

  • Events (3)
  • News (78)
  • Press releases (84)

LATEST NEWS

  • Chronolife and Infiniwell join forces to deliver end-to-end remote health monitoring services March 22, 2023
  • Prophesee named in Best of MWC 2023 Awards by Android Authority February 28, 2023
  • Prophesee Announces Collaboration with Qualcomm to Optimize Neuromorphic Vision Technologies For the Next Generation of Smartphones, Unlocking a New Image Quality Paradigm for Photography and Video February 27, 2023
  • Prophesee named to La French Tech 120 February 20, 2023
  • Chronolife announces a strategic partnership with SAMI Advanced Electronics in Saudi Arabia February 14, 2023

CONTACT US

74, rue du Faubourg Saint-Antoine 75012 Paris
+33 1 76 21 47 50
contact@ibionext.com

LEGAL NOTICES

  • Cookies Policy
  • Privacy Policy
  • Terms of use
© 2023 iBionext. All rights reserved